Tom Frohlich

CIK 1823925 · View on SEC EDGAR ↗

Insider

First SEC filing: May 1, 2025 · Latest: May 1, 2025

On this page

Insider at

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 2 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

2 other filings hidden
Date Ticker Code Shares Price Value Owned after Δ own A/D vs now
May 16, 2025 JBIO P 6,000 $7.40 $44,400 6,000 Direct Acquired 190.9% (price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date Ticker Security Underlying Exercise price Expiration Shares A/D
Feb. 12, 2026 JBIO Stock Option (Right to Buy) Common Stock (472,500) $14.81 Feb. 11, 2036 472,500 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 3 holdings

Securities held when first becoming an insider, per SEC Form 3.

Date Ticker Security Shares Ownership
May 1, 2025 JBIO Stock Option (Right to Buy)→ Common Stock (931,131) 931,131 Direct
May 1, 2025 JBIO Stock Option (Right to Buy)→ Common Stock (1,060,732) 1,060,732 Direct
May 1, 2025 JBIO Stock Option (Right to Buy)→ Common Stock (779,934) 779,934 Direct

Compensation (DEF 14A)

Matched by name from proxy statements (DEF 14A) — verify against the filing.

JBIO

President and Director
Fiscal year Salary Bonus Stock awards Option awards Non-equity incentive Pension change Other Total
2025 $621,970 $397,913 $9,799,759
2024 $146,920 $96,164 $1,364,396

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.